Our podium presentation:
Is market access for oncology treatments easier in England than for non-oncology treatments? An analysis of NICE single technology appraisals from 2017-2019
Will be presented on 4th November during breakout session 2 at 14:15
Abstract 1: Are patient access schemes and commercial access agreements essential for NICE to recommend access? A comparison of oncology and non-oncology appraisals
Abstract 2: Pricing and market access launch excellence: What are the key challenges facing companies today?
Abstract 3: Are acute therapies and curative drugs more affordable than chronic treatments in rare diseases? An analysis of the top 20 most expensive drugs in the US
Abstract 4: Was the evidence base for Yescarta and Kymriah sufficient to justify their cost and secure patient access across 5 markets?